269 related articles for article (PubMed ID: 37629155)
1. Parp Inhibitors and Radiotherapy: A New Combination for Prostate Cancer (Systematic Review).
Rivero Belenchón I; Congregado Ruiz CB; Saez C; Osman García I; Medina López RA
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629155
[TBL] [Abstract][Full Text] [Related]
2. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
[TBL] [Abstract][Full Text] [Related]
4. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Reilly NM; Yard BD; Pittman DL
Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Chalmers AJ; Lakshman M; Chan N; Bristow RG
Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
[TBL] [Abstract][Full Text] [Related]
9. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.
Murmann-Konda T; Soni A; Stuschke M; Iliakis G
Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628
[TBL] [Abstract][Full Text] [Related]
10. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
12. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.
Soni A; Li F; Wang Y; Grabos M; Krieger LM; Chaudhary S; Hasan MSM; Ahmed M; Coleman CN; Teicher BA; Piekarz RL; Wang D; Iliakis GE
Mol Cancer Ther; 2018 Oct; 17(10):2206-2216. PubMed ID: 29970481
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
Hilton JF; Hadfield MJ; Tran MT; Shapiro GI
Front Biosci (Landmark Ed); 2013 Jun; 18(4):1392-406. PubMed ID: 23747892
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy-Poly(ADP-ribose) Polymerase Inhibitor Combinations: Progress to Date.
Derby SJ; Chalmers AJ; Carruthers RD
Semin Radiat Oncol; 2022 Jan; 32(1):15-28. PubMed ID: 34861992
[TBL] [Abstract][Full Text] [Related]
20. The
Simoneau A; Xiong R; Zou L
Genes Dev; 2021 Sep; 35(17-18):1271-1289. PubMed ID: 34385259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
